This week's edition of Life Sciences weekly highlights includes news that EU industry, including MedTech Europe and EFPIA, published a joint statement calling for the withdrawal of the proposed AI Liability Directive, the European Commission has announced plans for a Critical Medicines Act to address essential medicines supply chain vulnerabilities which follows the EFPIA proposed action plan to address medicine shortages in Europe, the ABPI has strongly criticised the high Voluntary Scheme for Branded Medicines Pricing and Access (VPAG) payment rate of 22.9% for 2025, the Commission has initiated a comprehensive review of Regulation (EU) 316/2014, the Technology Transfer Block Exemption Regulation (TTBER) and accompanying Guidelines, and a European industry joint statement raises concerns about draft guidelines on Article 102 TFEU. Also included, is news that the IMDRF has released final guidelines on good machine learning practices in medical device development and another on risk characterisation for medical device software and software-specific risks, the UK government issued its response and a final Code of Practice for AI in Cyber Security, the MHRA launched a revised and expanded ILAP pathway for innovative medicines from March 2025, a new regulatory framework for medicines manufactured at the ‘point of care’ (POC) and modular manufacturing came into force on 24 January 2025 and the MHRA has launched a consultation on regulatory guidance for individualised mRNA cancer immunotherapies, among other stories.